ARCUTIS BIOTHERAPEUTICS, INC.
Last · NasdaqGS$26.41+0.32 (+1.23%)close · yahoo · 14h ago
Market cap$3.32B125.7M sh
P/E · TTM120fwd 19.4 · eps 0.22
Beta1.58vs S&P 500
Div yield0.00%annual · TTM
52w range
$19.30$31.77
Volume1.6Msession
| Revenue | $464.0M |
|---|---|
| Operating income | $34.3M |
| Net income | $28.5M |
| Free cash flow | $14.7M |
| Operating margin | 7.4% |
| Net margin | 6.1% |
| Return on equity | 12.9% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-25
- Operating Cf Burn
- Cash Conversion Weak
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Conversion Weak — Cash conversion (CFO/Rev) -1.5%
- Accumulated Deficit High — Accumulated deficit / equity 601%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
$0.17
Est. revenue
141.7M
Earnings transcripts
Press & signals
- GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
- GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans